Disease · MONDO_0008538
temporal arteritis
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. temporal arteritis. Diseases, record MONDO_0008538. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0008538
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
Giant Cell Arteritis, Giant cell arteritis (disorder), Giant cell arteritis NOS (disorder), Horton disease, Horton's disease, Temporal arteritis (disorder), inflammation of temporal artery, temporal artery inflammation
- Open Targets
- Highest stage of its drugs
- Approval, for 2 of its 29 drugs, from DailyMed, EMA Human Drugs and TTD
- Open Targets
Drugs29
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| TOCILIZUMAB | CHEMBL1237022 | Antibody | Approval | DailyMed, EMA Human Drugs and TTD | 18 | 13 | 13 | Drugs and targets |
| UPADACITINIB | CHEMBL3622821 | Small molecule | Approval | EMA Human Drugs | 2 | 1 | 1 | Drugs and targets |
| PREDNISONE | CHEMBL635 | Small molecule | Phase 3 | ClinicalTrials.gov | 12 | 12 | 7 | Drugs and targets |
| METHYLPREDNISOLONE | CHEMBL650 | Small molecule | Phase 3 | ClinicalTrials.gov | 5 | 5 | 0 | Drugs and targets |
| PREDNISOLONE | CHEMBL131 | Small molecule | Phase 3 | ClinicalTrials.gov | 5 | 5 | 1 | Drugs and targets |
| SECUKINUMAB | CHEMBL1743068 | Antibody | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| ABATACEPT | CHEMBL1201823 | Protein | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| METHOTREXATE | CHEMBL34259 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| BOSENTAN | CHEMBL957 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| SIRUKUMAB | CHEMBL1743071 | Antibody | Phase 3 | ClinicalTrials.gov and TTD | 2 | 1 | 1 | Drugs and targets |
1 to 10 of 29
See all 29 drugsTargets23
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| NR3C1 | Glucocorticoid receptor | 11 | Glucocorticoid receptor agonist | Phase 3 | https://conductscience.org/library/genes/2908 | Drugs and targets |
| IL12B | Interleukin-12 | 2 | Interleukin-12 inhibitor; Interleukin-23 inhibitor | Phase 2 | https://conductscience.org/library/genes/3593 | Drugs and targets |
| IL23A | Interleukin-23 | 2 | Interleukin-23 inhibitor | Phase 2 | https://conductscience.org/library/genes/51561 | Drugs and targets |
| IL6R | Interleukin-6 receptor subunit alpha | 2 | Interleukin-6 receptor alpha subunit antagonist; Interleukin-6 receptor alpha subunit inhibitor | Approval | https://conductscience.org/library/genes/3570 | Drugs and targets |
| JAK1 | Tyrosine-protein kinase JAK1 | 2 | Tyrosine-protein kinase JAK1 inhibitor | Approval | https://conductscience.org/library/genes/3716 | Drugs and targets |
| JAK2 | Tyrosine-protein kinase JAK2 | 2 | Tyrosine-protein kinase JAK2 inhibitor | Approval | https://conductscience.org/library/genes/3717 | Drugs and targets |
| TNF | Tumor necrosis factor | 2 | TNF-alpha inhibitor | Phase 3 | https://conductscience.org/library/genes/7124 | Drugs and targets |
| CD80 | T-lymphocyte activation antigen CD80 | 1 | T-lymphocyte activation antigen CD80 inhibitor | Phase 3 | https://conductscience.org/library/genes/941 | Drugs and targets |
| CD86 | T-lymphocyte activation antigen CD86 | 1 | T-lymphocyte activation antigen CD86 inhibitor | Phase 3 | https://conductscience.org/library/genes/942 | Drugs and targets |
| CSF2RA | Granulocyte-macrophage colony-stimulating factor receptor | 1 | Granulocyte-macrophage colony-stimulating factor receptor antagonist | Phase 2 | https://conductscience.org/library/genes/1438 | Drugs and targets |
1 to 10 of 23
See all 23 targetsTrials38
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03725202 | A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis | Phase 3 | 429 | 2025-03-07 | Giant Cell Arteritis (GCA) | UPADACITINIB | Its record names the disease | ClinicalTrials.gov |
| NCT01791153 | An Efficacy and Safety Study of Tocilizumab (RoActemra/Actemra) in Participants With Giant Cell Arteritis (GCA) | Phase 3 | 251 | 2017-05-18 | Giant Cell Arteritis | PREDNISONE, TOCILIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02531633 | Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis | Phase 3 | 161 | 2019-05-31 | Giant Cell Arteritis | SIRUKUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00556439 | Abatacept for Treating Adults With Giant Cell Arteritis and Takayasu's Arteritis | Phase 2 | 97 | 2018-02-26 | Takayasu's Arteritis, Giant Cell Arteritis | ABATACEPT | Its record names the disease | ClinicalTrials.gov |
| NCT03600805 | Evaluation of Efficacy and Safety of Sarilumab in Patients With GCA | Phase 3 | 83 | 2022-01-14 | Giant Cell Arteritis | PREDNISONE, SARILUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT03827018 | KPL-301 for Subjects With Giant Cell Arteritis | Phase 2 | 70 | 2023-10-17 | Giant Cell Arteritis | MAVRILIMUMAB, PREDNISONE | Its record names the disease | ClinicalTrials.gov |
| NCT04633447 | A Study to Evaluate Guselkumab for the Treatment of Participants With New-onset or Relapsing Giant Cell Arteritis | Phase 2 | 53 | 2025-07-01 | Giant Cell Arteritis | GUSELKUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT03765788 | A Placebo-controlled Phase 2 Trial to Investigate the Safety and Efficacy of Secukinumab in Giant Cell Arteritis | Phase 2 | 52 | 2023-04-26 | Giant Cell Arteritis | SECUKINUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT01450137 | Tocilizumab for Patients With Giant Cell Arteritis | Phase 2 | 30 | 2019-02-12 | Giant Cell Arteritis | TOCILIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT03923738 | A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Tocilizumab (TCZ) Administered to Participants With Giant Cell Arteritis (GCA). | Phase 1 | 24 | 2021-12-22 | Giant Cell Arteritis | TOCILIZUMAB | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 38
See all 38 trialsComparisons in its trials13
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Mavrilimumab vs Placebo: deaths from any cause | 0 of 42 | 0 of 28 | 70 | NCT03827018 | Trial comparisons |
| Mavrilimumab vs Placebo: serious adverse events | 2 of 42 | 3 of 28 | 70 | NCT03827018 | Trial comparisons |
| Main Study: Guselkumab vs Main Study: Placebo: Main Study: Number of Participants With Treatment-emergent Serious Adverse Event (SAEs) | 6 of 35 | 0 of 18 | 53 | NCT04633447 | Trial comparisons |
| Main Study: Guselkumab vs Main Study: Placebo: Main Study: Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 34 of 35 | 17 of 18 | 53 | NCT04633447 | Trial comparisons |
| Secukinumab vs Placebo: Percentage of Participants With GCA Who Had Sustained Remission Until Week 52 | 16 of 27 | 2 of 25 | 52 | NCT03765788 | Trial comparisons |
| Secukinumab vs Placebo: Percentage of Participants in Remission at Week 12 | 22 of 27 | 12 of 25 | 52 | NCT03765788 | Trial comparisons |
| Secukinumab vs Placebo: Percentage of Participants in Sustained Remission Until Week 28 | 19 of 27 | 6 of 25 | 52 | NCT03765788 | Trial comparisons |
| TCZ IV 7 mg/kg Q4W vs TCZ IV 6 mg/kg Q4W: deaths from any cause | 0 of 24 | 0 of 22 | 46 | NCT03923738 | Trial comparisons |
| TCZ IV 7 mg/kg Q4W vs TCZ IV 6 mg/kg Q4W: serious adverse events | 3 of 24 | 1 of 22 | 46 | NCT03923738 | Trial comparisons |
| Tocilizumab vs Placebo: Number of Relapse Free Patients | 17 of 20 | 2 of 10 | 30 | NCT01450137 | Trial comparisons |
1 to 10 of 13
See all 13 comparisons in its trialsPapers from its trials42
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0008538
GET https://conductscience.org/api/diseases/v1/MONDO_0008538/drugs?page=2